Sirenas, BMS partner on drug discovery for "challenging" targets

Sirenas LLC (San Diego, Calif.) and Bristol-Myers Squibb Co. (NYSE:BMY) partnered to use Sirenas' ATLANTIS drug discovery platform against several undisclosed "challenging" targets.

ATLANTIS uses machine learning to discover microbiome-derived metabolites, which then form the basis for synthetic chemistry or lead optimization to develop immuno-modulatory candidates...